Replies

is it true that Fluoroquinolones can negatively affect the mitochondria?

grok:

https://x.com/i/grok?conversation=2034642096884482291

Yes, there is substantial scientific evidence supporting the claim that fluoroquinolones (a class of antibiotics including ciprofloxacin, levofloxacin, moxifloxacin, and others) can negatively affect mitochondria, often leading to mitochondrial dysfunction, oxidative stress, and related damage.

This is not just anecdotal or fringe — it’s backed by multiple peer-reviewed studies, including in vitro (cell-based), animal models, and mechanistic investigations. The effects are thought to contribute to some of the serious, sometimes long-lasting or disabling side effects associated with these drugs (e.g., tendinopathy, neuropathy, neuropsychiatric issues, and multisystem toxicity sometimes called fluoroquinolone-associated disability or FQAD).

Key Mechanisms and EvidenceFluoroquinolones primarily target bacterial DNA gyrase and topoisomerase IV to kill bacteria. However, human cells have related enzymes (topoisomerase IIα and IIβ) in mitochondria (which evolved from ancient bacteria and retain some bacterial-like features).

Fluoroquinolones can interfere with these mitochondrial enzymes, leading to:Inhibition of mitochondrial DNA (mtDNA) replication — This causes depletion of mtDNA copy number, impaired mitochondrial biogenesis, and reduced energy production (ATP).

Oxidative stress — Increased production of reactive oxygen species (ROS), which damages mitochondrial membranes, proteins, and DNA.

Disruption of the electron transport chain — Effects on complexes I and IV, leading to reduced mitochondrial function.

Other downstream effects — Mitochondrial membrane potential loss, altered redox status, and cellular dysfunction in tissues like tendons, nerves, retina, and pancreas.

Studies have shown these effects occur at clinically relevant concentrations (therapeutic doses), and they can persist or worsen after stopping the drug in susceptible individuals.

Supporting Research HighlightsMultiple studies (e.g., from 2009–2025) demonstrate fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human tendon cells, retinal cells, and other models. Mitochondria-targeted antioxidants like MitoQ have been shown to protect against these effects in some experiments.

Proteomic analyses (e.g., recent 2025 work) identified specific off-target interactions with mitochondrial proteins (AIFM1 and IDH2), confirming disruption of the electron transport chain.

In vivo and in vitro evidence links this to tendon toxicity, neuropathy, and other adverse events, with mtDNA as a key target via topoisomerase inhibition.

Reviews and collaborative investigations (including FDA-related petitions around 2013–2016) note that fluoroquinolones affect mammalian mitochondrial topoisomerase II, contributing to toxicities.

The FDA has issued black box warnings for fluoroquinolones since around 2008–2016, focusing on disabling side effects (tendons, nerves, muscles, joints, CNS), but it has not always explicitly highlighted “mitochondrial toxicity” in labeling — though citizen petitions and safety reviews referenced it as a potential mechanism.

Not everyone experiences these effects — they appear idiosyncratic (more common in certain people, possibly due to genetic factors, age, or impaired drug metabolism). The risks are why fluoroquinolones are now recommended only for serious infections where alternatives aren’t suitable.If you’re concerned about personal exposure or symptoms, consult a healthcare provider familiar with these issues, as management can involve supportive care (e.g., antioxidants in some contexts, though not standard treatment).